ALKS - Rasio utang marang kapitalisasi buku Alkermes PLC

Alkermes plc (ALKS) generates revenue from the sale of treatments for addiction and schizophrenia, while the spin-off of its oncology division and breakthroughs in narcolepsy therapy drive growth, which currently stands at 0.92. Complex injection patents and stringent FDA oversight serve as a moat for the business. This price action chart on GURU.Markets illustrates asset dynamics within the CNS drug ecosystem.

ALKS (Alkermes Corp) riwayat Utang marang nilai buku saka 04.07.2022 nganti 27.10.2026

Alkermes PLC (ALKS) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:

Rega saham Alkermes plc|ALKS - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar Alkermes Corp|ALKS - Nilai Dipunlarasaken Utang lan Kas

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Alkermes|ALKS - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku alkermes.com|ALKS - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Alkermes plc|ALKS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Alkermes Inc.|ALKS - Gunggung tanggungan utang perusahaan|Rasio utang marang kapitalisasi buku Alkermes Corp

Ringkesan analitik perusahaan:Alkermes plc

For Alkermes plc (ALKS), whose expenditures on multi-year clinical trials for psychotropic agents are colossal, the total debt-to-book capitalization ratio reflects the balance between leverage and equity. A decrease in this ratio confirms financial autonomy and the absence of default risk, whereas excessive conservatism in borrowing may limit the pace of development for innovative drug delivery systems.

Pesaing Alkermes plc (ALKS)

Utang-utang marang kapitalisasi buku AVDL (Avadel Pharmaceuticals)|atai.life - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku GH Research (GHRS)|MNMD: Rasio utang marang aset resik|CMPS (Compass Pathways) - Rasio utang marang kapitalisasi buku|LB Corp (LBRX) - Utang marang nilai buku|DRUG (Bright Minds Biosciences) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku vandapharma.com (VNDA)|Cybin Inc. (CYBN) - Utang marang nilai buku|Rasio utang marang aset resik ANRO (Alto Neuroscience Inc)|NRx Pharma (NRXP) - Rasio utang marang kapitalisasi buku|Cingulate Inc - Rasio utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku SILO (Silo Pharma, Inc.)|China Pharma Holdings (CPHI) - Utang-utang marang aset resik|Utang marang nilai buku CMND|Psyence Biomedical Ltd (PBM) - Utang-utang marang nilai buku|Utang-utang marang kapitalisasi buku SPRC|Utang marang nilai buku Seelos Therapeutics Inc|Virpax Pharmaceuticals (VRPX) - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik KRTX (karunatx.com)